Gauthier Péan de Ponfilly

Gauthier Péan de Ponfilly

Auto-generated profile, based on publicly available information

Gauthier Péan de Ponfilly

Service de microbiologie clinique, groupe hospitalier Paris Saint-Joseph, 75014 Paris, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
KCKhalil Chaïbi
Khalil Chaïbi
GPGauthier Péan de Ponfilly
Gauthier Péan de Ponfilly
Laurent DORTETLaurent DORTET
Laurent DORTET
JZJean-Ralph Zahar
Jean-Ralph Zahar
BPBenoît Pilmis
Benoît Pilmis
Ventilator-associated pneumonia is a frequent cause of ICU-acquired infections. These infections are associated with high morbidity and mortality. The increase in antibiotic resistance, particularly among Gram-negative bacilli, makes the choice of empiric antibiotic therapy complex for physicians. Multidrug-resistant organisms (MDROs) related infections are associated with a high risk of initial therapeutic inadequacy. It is, therefore, necessary to quickly identify the bacterial species involved and their susceptibility to antibiotics. New diagnostic tools have recently been commercialized to assist in the management of these infections. Moreover, the recent enrichment of the therapeutic arsenal effective on Gram-negative bacilli raises the question of their place in the therapeutic management of these infections. Most national and international guidelines recommend limiting their use to microbiologically documented infections. However, many clinical situations and, in particular, the knowledge of digestive or respiratory carriage by MDROs should lead to the discussion of the use of these new molecules, especially the new combinations with beta-lactamase inhibitors in empirical therapy. In this review, we present the current epidemiological data, particularly in terms of MDRO, as well as the clinical and microbiological elements that may be taken into account in the discussion of empirical antibiotic therapy for patients managed for ventilator-associated pneumonia.

16 June 2020 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
ELEmmanuel Lecorche
Emmanuel Lecorche
GPGauthier Pean de Ponfilly
Gauthier Pean de Ponfilly
FMFaiza Mougari
Faiza Mougari
HBHanaa Benmansour
Hanaa Benmansour
EPElodie Poisnel
Elodie Poisnel
ECEmmanuelle Cambau
Emmanuelle Cambau
Invasive cardiovascular infections by Mycobacterium chimaera associated with open-heart surgery have been reported worldwide since 2013. Here, we report a case of a 61 year old man, without any other particular medical background, who underwent cardiac surgery for replacing part of the ascending aorta by a bio-prosthetic graft. Eighteen months later, the patient was painful at the lower back with fever. A pyogenic vertebral osteomyelitis due to M. chimaera associated to graft infection was diagnosed after 6 months of sub-acute infection. The patient presented a disseminated disease with cerebral lesions, chorioretinitis, and chronic renal failure. Despite adequate antimicrobial treatment and graft explantation, the patient died after 6 years. We reviewed the literature on M. chimaera infections associated with open-heart surgery. The worldwide outbreak has been explained by airborne bioaerosol generated by the 3T heater–cooler unit (HCU) used during cardiac by-pass surgical procedures. These infections are difficult to diagnose because of a long latency period (up to several years), with no specific symptoms and a highly specialized microbiological diagnosis. The treatment is based on antibiotics and surgery. These infections are also difficult to treat, since the mortality rate is high around 50%. Prevention is necessary by modifying the use of HCUs in operating rooms.

1 December 2021 in Journal of Infection
Verified
Journal Article
Closed access
GPGauthier Péan de Ponfilly
Gauthier Péan de Ponfilly
ACAnthony CHAUVIN
Anthony CHAUVIN
MSMaud Salmona
Maud Salmona
HBHanaa Benmansour
Hanaa Benmansour
BBBéatrice Bercot
Béatrice Bercot
HJHervé Jacquier
Hervé Jacquier

1 June 2021 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
GPGauthier Péan de Ponfilly
Gauthier Péan de Ponfilly
HBH. Benmansour
H. Benmansour
VMV. Manda
V. Manda
ELE. Lecorche
E. Lecorche
FMF. Mougari
F. Mougari
ECE. Cambau
E. Cambau

7 January 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
RSRindala Saliba
Rindala Saliba
AMAssaf Mizrahi
Assaf Mizrahi
PGPéan de Ponfilly Gauthier
Péan de Ponfilly Gauthier
LALe Monnier Alban
Le Monnier Alban
JZJean-Ralph Zahar
Jean-Ralph Zahar
BPBenoît Pilmis
Benoît Pilmis
Overconsumption of antibiotics in hospitals has led to policy implementation, including the control of antibiotic prescriptions. The impact of these policies on the evolution of antimicrobial resistance remains uncertain. In this work, we review the possible limits of such policies and focus on the need for a more efficient approach. Establishing a causal relationship between the introduction of new antibiotics and the emergence of new resistance mechanisms is difficult. Several studies have demonstrated that many resistance mechanisms existed before the discovery of antibiotics. Overconsumption of antibiotics has worsened the phenomenon of resistance. Antibiotics are responsible for intestinal dysbiosis, which is suspected of being the source of bacterial resistance. The complexity of the intestinal microbiota composition, the impact of the pharmacokinetic properties of antibiotics, and the multiplicity of other factors involved in the acquisition and emergence of multidrug-resistant organisms, lead us to think that de-escalation, in the absence of studies proving its effectiveness, is not the solution to limiting the spread of multidrug-resistant organisms. More studies are needed to clarify the ecological risk caused by different antibiotic classes. In the meantime, we need to concentrate our efforts on limiting antibiotic prescriptions to patients who really need it, and work on reducing the duration of these treatments.

1 March 2022 in Infectious Diseases Now
Verified
Journal Article
Closed access
BPBenoît Pilmis
Benoît Pilmis
GPG. Péan de Ponfilly
G. Péan de Ponfilly
EFE. Farfour
E. Farfour
ARA.-G. Ranc
A.-G. Ranc
VFV. Fihman
V. Fihman
AMA. Le Monnier
A. Le Monnier